Dr. Omer Khalid, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 232
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
VA license 0101260793
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cjw Medical Center Richmond, VA
- Bon Secours St Francis Medical Center Midlothian, VA
- Henrico Doctors' Hospital Richmond, VA
Medical groups
- Gastrointestinal Specialists LLC (81 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 232
- Services billed
- 362
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 115 | 115 |
| Ultrasound scan of organ tissue for measuring elasticity | 96 | 90 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 92 | 90 |
| Established patient office or other outpatient visit, 30-39 minutes | 74 | 56 |
| Limited ultrasound scan of abdomen | 59 | 56 |
| Complete ultrasound scan of abdomen | 37 | 36 |
| Biopsy of large bowel using a flexible endoscope | 36 | 36 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 29 | 27 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 28 | 27 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 28 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in North Chesterfield, VA | 90 |
| Pantoprazole Sodium Other prescribers in North Chesterfield, VA | 65 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in North Chesterfield, VA | 48 |
| Linzess (linaclotide) Other prescribers in North Chesterfield, VA | 40 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in North Chesterfield, VA | 39 |
| Esomeprazole Magnesium Other prescribers in North Chesterfield, VA | 20 |
| Colestipol Hcl Other prescribers in North Chesterfield, VA | 20 |
| Dicyclomine Hcl Other prescribers in North Chesterfield, VA | 17 |
| Azathioprine Other prescribers in North Chesterfield, VA | 15 |
| Famotidine Other prescribers in North Chesterfield, VA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 52 payments worth $1,167 in total to this clinician.
| AbbVie Inc. | $777 |
|---|---|
| Genzyme Corporation | $88.24 |
| Pfizer Inc. | $62.14 |
| Ipsen Biopharmaceuticals, Inc | $61.13 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.51 |
| Janssen Biotech, Inc. | $41.11 |
| Takeda Pharmaceuticals U.S.A., Inc. | $34.73 |
| Lilly USA, LLC | $21.08 |
| Food and Beverage | $1,167 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $363,298 in research payments for these studies, mostly to the institutions running them.
- A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - Roche Cancer Screening Collection Study
Genentech, Inc. - Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presume…
Boehringer Ingelheim International GmbH - A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - 17 b-hydroxysteroid dehydrogenase type 13 minimization for the treatme
GlaxoSmithKline, LLC. - Study of DONQ52 in Active Celiac Disease
Chugai Pharmaceutical Co., Ltd. - A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/…
Boehringer Ingelheim International GmbH - Caris Biorepository Research Protocol
Caris Mpi, Inc. · Recruiting · NCT01499394 - Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132)
Bausch Health US, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.